A Novel RGD-independent Cell Adhesion Pathway Mediated by Fibronectin-bound Tissue Transglutaminase Rescues Cells from Anoikis*

Elisabetta A. M. Verderio‡, Dilek Telci‡, Afam Okoye‡, Gerry Melino§, and Martin Griffin¶

From the ‡Department of Life Sciences, Nottingham Trent University, Clifton Lane, Nottingham NG11 8NS, United Kingdom, the §Department of Experimental and Biochemical Sciences, D26/F153, University of Rome “Tor Vergata,” 00133 Rome, Italy, and the ¶Medical Research Council, Toxicology Unit, Hodgkin Building, Leicester University, Leicester LE1 9HN, United Kingdom

Specific association of tissue transglutaminase (tTG) with matrix fibronectin (FN) results in the formation of an extracellular complex (tTG-FN) with distinct adhesive and pro-survival characteristics. tTG-FN supports RGD-independent cell adhesion of different cell types and the formation of distinctive RhoA-dependent focal adhesions following inhibition of integrin function by competitive RGD peptides and function blocking anti-integrin antibodies α5β1, Association of tTG with its binding site on the 70-kDa amino-terminal FN fragment does not support this cell adhesion process, which seems to involve the entire FN molecule. RGD-independent cell adhesion to tTG-FN does not require transamidating activity, is mediated by the binding of tTG to cell-surface heparan sulfate chains, and is dependent on the function of protein kinase Cα, and leads to activation of the cell survival focal adhesion kinase. The tTG-FN complex can maintain cell viability of tTG-null mouse dermal fibroblasts when apoptosis is induced by inhibition of RGD-dependent adhesion (anoikis), suggesting an extracellular survival role for tTG. We propose a novel RGD-independent cell adhesion mechanism that promotes cell survival when the anti-apoptotic role mediated by RGD-dependent integrin function is reduced as in tissue injury, which is consistent with the externalization and binding of tTG to fibronectin following cell damage/stress.

Subtle changes in the extracellular matrix (ECM) complexity/tissue architecture may be crucial for the regulation of the apoptotic machinery leading to anoikis (1, 2). Such a process occurs during tissue injury when the composition and integrity of the ECM are altered in several significant ways (3). A central component of the ECM, which regulates adhesion-dependent survival signaling, is the adhesive glycoprotein fibronectin (FN) (4). FN binds to cell-surface matrix receptors, primarily the α5β1 integrins, through the Arg-Gly-Asp (RGD) cell-binding site within the Type III10 domain. The importance of the RGD cell-binding domain in adhesion-mediated cell survival has been demonstrated by employing synthetic peptides containing the RGD motif, which induce apoptosis in many cell types, by acting as competitive inhibitors of FN-integrin interaction and activators of caspase 3 (5, 6). A comparable scenario may occur in wounding and inflammatory conditions, whereby fragmentation of FN can lead to detachment-induced apoptosis (5, 7). However, the RGD cell-binding domain of FN is not sufficient in isolation to regulate cell survival, which must be sustained by other critical FN domains such as the C-terminal heparin-binding domain (HepII) (7, 8), known to synergistically interact with heparan sulfate proteoglycans (HSPG) receptors and integrin α5β1 (9). Evidence is also accumulating to suggest that changes in the molecular structure and composition of the FN matrix may provide new signals to regulate cell shape, migration, and proliferation. Alterations to the conformation of FN either by multimerization (10) or heterotypic association with other matrix molecules (11) could reveal biologically active neo-epitopes, which regulate cell responses via the induction of cytoskeleton assembly (12). Modulation of the FN matrix may therefore also be fundamental in the regulation of adhesion-related apoptosis.

One protein that binds with high affinity specialized FN domains and modulates the function of FN is tissue-type transglutaminase (tTG, TG-2) (10, 13, 14). tTG is a multifunctional protein implicated in diverse normal and pathological processes (15) but more specifically is regarded as an important component of cell/tissue defense in response to cell damage and stress (16, 17). tTG differs from the other transglutaminases in its enzymatic properties and structure, with a large number of residues including neo-epitopes, which regulate cell responses via the induction of cytoskeleton assembly (12). Modulation of the FN matrix may therefore also be fundamental in the regulation of adhesion-related apoptosis.

This paper is available online at http://www.jbc.org.
and it appears as a globular protein bound to the N-terminal portion of FN interacting either with the Type I–Ia motif (24) or with a sequence within the gelatin-binding domain of FN (I1–I2–I3–I4–I5–I6) (13).

The involvement of tTG in the adhesion of multiple cell types is now consolidated (25, 26); however, the molecular mechanism and its physiological significance remain controversial. It has been proposed that tTG enhances cell adhesion through matrix remodeling, via protein cross-linking (10, 26); however, recent findings suggest that tTG involvement in cell-matrix interaction is independent from its transamination activity (19, 27, 28). Cell-surface tTG might act as an adhesion co-receptor of integrins β1 and β3 by mediating cell adhesion to the gelatin-binding domain of FN (27) or, conversely, act as an independent adhesion protein by specific binding to α5β1 integrins (28).

In the current study we have explored the involvement of tTG in FN-mediated cell survival, starting with the hypothesis that the ECM function of tTG is strictly dependent on its association with FN, and that tTG and FN reciprocally modulate each others functions following complex formation. We report that FN-bound tTG supports a novel RGD-independent cell adhesion process, which is mediated by the direct binding of tTG to the cell surface through a mechanism that is critically dependent on cell-surface heparan sulfate and activation of protein kinase Cα (PKCα). We describe that FN-bound tTG, but not FN, can rescue tTG-deficient mouse dermal fibroblasts from apoptosis induced by inhibition of RGD-dependent cell adhesion (anosia), with maintenance of cell viability. Our findings suggest that matrix FN with bound tTG is functionally distinct from either protein acting in isolation and suggest a novel RGD-independent pathway that may be important in cell survival under conditions of cell damage/stress.

**EXPERIMENTAL PROCEDURES**

**Reagents and Antibodies**—Mouse monoclonal antibodies included anti-integrin β1 (JB1A) and α5 (P6D6) (Chemicon); vinculin and tubulin (Sigma-Aldrich); and tTG (Cat74) (Neomarkers). Rabbit polyclonal antibodies included anti-human fibronectin (Sigma-Aldrich) and anti-human Tyrrp/p97–99–FAK (Upstate Biotechnology). The tTG inhibitor R283 (19) was synthesized by R. Saint and I. Coutts, Nottingham Trent University. Purified guinea pig liver tTG was either obtained by Sigma-Aldrich or purified according to Leblanc et al. (29). Human plasma FN and FN proteolytic fragments, CTP-S, and synthetic RGD-specific peptides (GRGDTP and GRGDSP) were from Sigma-Aldrich and control RAD peptide (GRADSP) was from Calbiochem. Heparitinase (EC4.2.2.8) was from Sigma-Aldrich, and chondroitinase ABC (pro-tease-free) from Seikagaku Corporation. The PKCα inhibitor GO6976 was from Calbiochem.

**Cell Lines**—Primary human osteoblasts (HOB) were provided by S. Downes (University of Nottingham, Nottingham, UK) and maintained in Dulbecco’s modified Eagle’s medium (DMEM) as we previously described (30). Swiss 3T3 albino fibroblasts were obtained from American Type Culture Collection and maintained in DMEM supplemented with 10% fetal calf serum, 2 mM glutamine, and penicillin/streptomycin (100 units/ml and 100 μg/ml, respectively). Transfected Swiss 3T3 fibroblasts, displaying inducible expression of tTG (clone TG3), were cultured and induced as described by Verderio et al. (22). Primary mouse dermal fibroblasts (MDF) were isolated from the skin of tTG-deficient (MDF-TG−/−) and wild type (MDF-TG+/+) 9-months-old mice, described as described by Laurenen and Melino (31).

**Imobilization of tTG on FN and Amino-terminal FN Fragments—** 96-well plates were coated with human plasma FN (5 μg/ml) or with the 70 kDa (42 μg/ml), 45 kDa (54 μg/ml), and 30 kDa (54 μg/ml) proteolytic fragments of FN in 50 mM Tris–HCl, pH 7.4, 50 μg/ml, by incubation at 4 °C for ~15 h. Concentrations of FN and FN fragments were optimal to saturate tissue culture plastic (TCP), as measured by an ELISA-based assay with anti-FN antibodies in 9.6-cm²-wells. The assay was performed in 50 mM Tris–HCl and was labeled anti-rabbit IgG (1/5000). FN fragments were in a 30-, 60-, and 90-fold stoichiometric excess, respectively, of control FN. For tTG immobilization, the FN solution was removed, the wells were washed once in 50 mM Tris–HCl, pH 7.4, and then incubated with purified guinea pig liver tTG (20 μg/ml) in phosphate-buffered saline (PBS) containing 2 mM EDTA, 100 μg/ml. After 1 h at 37 °C, the tTG solution was removed and wells were washed once in 50 mM Tris–HCl, pH 7.4, and once in serum-free culture medium before cell seeding. In some experiments FN-coated plates were blocked with 3% (w/v) lipid milk protein (Marvel) in PBS at 37 °C for 30 min and then washed twice with 50 mM Tris–HCl, pH 7.4, prior to tTG immobilization. The presence of tTG immobilized on FN was confirmed by an ELISA-type assay using Cat74 as we previously described (26). The transamidating activity of the immobilized tTG was determined by the incorporation of biotinylated cadaverine into FN as previously described (26) and compared with the activity of free tTG standard. Data are expressed as absorbance 450 nm with 5 mM Ca2+ in the reaction buffer minus background absorbance values with one EDTA.

**Cell Adhesion Assay—** Exponentially growing cells were detached using 0.25% (w/v) trypsin in 5 mM EDTA, collected into medium containing a ~7% (v/v) fetal calf serum, washed twice with medium without fetal calf serum, and then plated onto 96-well plates (2 × 103 cells/well), coated with FN or FN fragments, with and without immobilized tTG. After a maximum of 20 min incubation (to minimize the secretion of any endogenous protein) at 37 °C in a 5% CO2 atmosphere, cells were fixed in 3.7% (w/v) paraformaldehyde in PBS, permeabilized in 0.1% (v/v) Triton X-100 in PBS, and stained with May-Grünwald and Gimsa stain (26). In some cases cells were pre-treated for 15 h with 1 mM cycloheximide before plating, to rule out any effects of endogenous secreted cell adhesion molecules. Digital images of 3 non-overlapping fields covering the central portion of each well were captured using a video digital camera (Olympus DP10) and examined using the Image Analysis program Scion Image (National Institute of Health). At least 9 images of separate fields per sample were examined for a total of at least 400 cells in the FN control. The number of attached cell particles in each field was measured by “thresholding” and “particle analysis” and the spread cells by “density slicing.”

**Cytoskeletal Staining—** Actin stress fibers were visualized using fluorescein isothiocyanate (FITC)-labeled phalloidin and focal adhesions by staining for vinculin. Cells were seeded in 0.79-cm²-wells of chamber slides (9 × 106 cells/well) previously coated with FN and tTG-FN and allowed to adhere for 2 h. Cells were fixed in 3.7% (w/v) paraformaldehyde in PBS and permeabilized in 0.1% (v/v) Triton X-100 in PBS. For actin stress fibers, cells were then blocked in PBS buffer supplemented with 5% (w/v) dry milk and then incubated with FITC-labeled phalloidin (20 μg/ml) in blocking buffer. For localization of vinculin, cells were blocked in PBS buffer containing 5% (w/v) bovine serum albumin and then incubated with mouse monoclonal anti-vinculin antibody (1:100) in blocking buffer. Bound antibody was revealed by incubation with rabbit anti-mouse IgG-FITC (1:100) (Dako) in blocking buffer. Coverslips were mounted with Vectashield mountant containing propidium iodide (Vector Laboratories) and examined by laser confocal microscopy using a Leica TCS NT system (Leica Lasertechnet). Consecutively scanning sections (at least 200 μm) of the incubation site of cells were overlaid as an extended focus image, and imaged cells (at least 8 random fields, at least 100 cells in FN control) were scored for actin stress fiber formation with the aid of the Leica TCSNT (version 1.5–451) image processing menu.

**Inhibition of Integrin-mediated Cell Adhesion—** Cells in suspension (2 × 105 cells/ml) were incubated with GRGDTP synthetic peptide (32) (50 μg/ml, ~75 μM, 100 μg/ml ~150 μM, or 200 μg/ml ~300 μM). Some experiments were reproduced using the FN-protein GRGDSP peptide. Alternatively, cells in suspension (2 × 106 cells/ml) were incubated with function blocking anti-integrin antibodies (JB1A, 40 μg/ml; and P6D6, 30 μg/ml). All incubations were performed in serum-free medium at 37 °C in an 8% oxygen atmosphere. Cells in suspension were seeded in 0.79-cm²-wells. After 30 min cell adherence, the medium was removed, cells were allowed to recover for ~30 min in serum-containing DMEM, and then were seeded in 0.79-cm²-wells of chamber slides (45 × 103 cells/well).

**Quantification of Anoikis and Measurement of Cell Viability—** For fluorochrome labeling of DNA strand breaks, 6 × 105 cells seeded on 9.6-cm²-wells were pre-coated with FN and tTG-FN in the presence or absence of RGD peptide. After 15 h incubation at 37 °C in a 5% CO2 atmosphere, all cells (adhered and non-adhered) were collected, washed twice in PBS, resuspended at the final concentration of 1.2 × 106 cells/ml, and fixed in suspension by addition of one volume of
RGD-independent Cell Adhesion by Tissue tTG-FN Complex

RESULTS

Tissue Transglutaminase Bound to FN Supports RGD-independent Cell Adhesion of Different Cell Types—Previous work using fluorescent microscopy and immunogold electron microscopy demonstrated a close association of tTG with FN at the cell surface/pericellular matrix (20, 22), consistent with the in vitro-specific binding of the enzyme with human plasma FN (13, 24). To investigate how tTG in complex with FN affects cell adhesion, we first bound purified guinea pig liver tTG to human plasma FN coated onto tissue culture plastic (TCP). EDTA was included in the reaction to inhibit tTG transamidating activity. Measurement of binding by an ELISA-type assay showed that FN, immobilized at the saturating concentration of 5 μg/ml, bound a saturating amount of tTG when incubated with 20 μg/ml free tTG (Fig. 1A). Using this initial matrix model of immobilized FN with bound tTG (tTG-FN), the contribution tTG to FN cell adhesion was examined by inhibiting integrin-mediated RGD-dependent cell adhesion with competitive concentrations of soluble RGD peptides. HOBs were selected as the initial cell model because they preferentially adhere on FN in vitro, demonstrate an enhanced spread morphology on biomaterials coated with tTG-FN (33), and are characterized by a well defined pattern of integrin cell-surface receptors, consisting mainly of RGD-binding β1 subunit paired with α5, αv, α3, α5, and αv subunits (34). In the absence of RGD peptide, attachment to tTG-FN was comparable with FN (Fig. 1B, upper panel), although cell spreading appeared to be enhanced on tTG-FN (Fig. 1B, lower panel). At 50 and 100 μg/ml RGD peptide, attachment on FN was significantly reduced (typically to 30–50% of control values on FN) (Fig. 1B, upper panel), but attachment to tTG-FN was not significantly inhibited at these same RGD peptide concentrations. Cell attachment to tTG-FN in the presence of 100 μg/ml RGD peptide was 85–95% of control cell attachment to FN without RGD peptide. Only at 200 μg/ml RGD peptide was cell attachment to tTG-FN significantly lower in comparison to control FN without RGD peptide. At 500 μg/ml RGD peptide, attachment to tTG-FN was ~70% of control and ~500 (Swiss 3T3). D, comparison of HOB cell attachment to TCP with increasing concentrations of bound tTG (20–50 μg/ml) and TCP with bound FN (5 μg/ml) in complex with tTG (20–50 μg/ml). Cell attachment was assessed and expressed as described above (RGD peptide was 100 μg/ml). Mean attachment values ± S.D. on FN control were 214 ± 22. Total cells analyzed in control sample were ~700. RGD-independent cell attachment to TCP with bound tTG did not significantly differ from cell attachment to TCP at any tTG concentration.

Fig. 1. tTG bound to FN but not tissue culture plastic supports RGD-independent cell adhesion. A, relative levels of tTG bound to coated FN at increasing concentrations of free tTG. Data are expressed as mean ± S.D. absorbance at 450 nm and represent one typical experiment undertaken in triplicate. Background absorbance (in the range of 0.02–0.15) was subtracted from data. The level of tTG bound to fibronectin (FN) after incubation with 20 μg/ml free tTG is significantly different from the level after incubation with 10 μg/ml, but not 30–50 μg/ml tTG. The level of tTG bound to tissue culture plastic (TCP) represents the positive experimental control. B, RGD-independent cell adhesion of HOB cells and Swiss 3T3 fibroblasts (C) in response to tTG-FN. Cell attachment (upper graphs in B and C) and cell spreading (lower graphs in B and C) on FN and tTG-FN were assessed 20 min after seeding cells pre-incubated with increasing concentrations of RGD synthetic peptide (0–200 μg/ml) (RGD 0–200), as described under “Experimental Procedures.” Insets in B and C show cell attachment (upper insets) and spreading (lower insets) on FN when cells were pre-incubated with equivalent concentrations of control RAD peptide (RAD 0–200). Each point represents the mean number of attached cells (cell attachment) or the mean percentage of spread cells (cell spreading) ± S.D. Data are expressed as percentage of control values on FN, which represents 100% and represent one of at least 3 separate experiments performed in triplicate. Mean attachment values ± S.D. on FN control were 306 ± 53 (HOB) and 166 ± 8 (Swiss 3T3) in upper graphs, 246 ± 13 (HOB) and 155 ± 14 (Swiss 3T3) in lower graphs, and 82 ± 2 (HOB) and 86 ± 3 (Swiss 3T3) in lower insets; total cells analyzed in control sample were ~900 (HOB) and ~500 (Swiss 3T3). D, comparison of HOB cell attachment to TCP with increasing concentrations of bound tTG (20–50 μg/ml) and TCP with bound FN (5 μg/ml) in complex with tTG (20–50 μg/ml). Cell attachment was assessed and expressed as described above (RGD peptide was 100 μg/ml). Mean attachment values ± S.D. on FN control were 214 ± 22. Total cells analyzed in control sample were ~700. RGD-independent cell attachment to TCP with bound tTG did not significantly differ from cell attachment to TCP at any tTG concentration.
this higher concentration, the RGD peptide may in part act nonspecifically, because the control RAD peptide also led to a small reduction in cell attachment at 200 μg/ml (Fig. 1B, upper inset). Incubation of cells with RGD peptide significantly reduced cell spreading on FN (Fig. 1B, lower panel), typically to 10–50% of control value at 100 μg/ml RGD peptide, but as for cell attachment, cell spreading was only partially reduced on tTG-FN at 50 and 100 μg/ml RGD peptide (usually to 65–85% of control values on FN). Swiss 3T3 fibroblasts displayed a comparable response to HOB cells on the tTG-FN complex. Attachment (Fig. 1C, upper panel) and spreading (Fig. 1C, lower panel) of Swiss 3T3 fibroblasts to FN was significantly decreased with excess RGD peptide, in a more sensitive way than in osteoblasts (typically to 25–35% of control at 100 μg/ml RGD peptide), but was restored to control levels when cells were seeded onto tTG-FN at 50 and 100 μg/ml RGD peptide. An epithelial-like cell line (ECV304) also adhered more efficiently on tTG-FN than FN in the presence of excess RGD peptide (Fig. Suppl. 1). When cells were seeded onto TCP coated with tTG without prior immobilization of FN, cell attachment was found to be negligible at concentrations ranging from 20 to 50 μg/ml of tTG, in the absence or presence of competitive RGD peptide (Fig. 1C). Plates were coated with saturating amounts of FN, and blocking of FN-coated wells with 3% nonfat milk protein prior to tTG immobilization did not affect RGD-independent cell attachment and spreading supported by the tTG-FN matrix formed in the absence of blocking (data not shown). These findings clearly indicate that the complex of tTG bound to FN is the essential component for the RGD-independent cell adhesion to occur. Association of purified tTG to free human plasma FN in solution prior to immobilization onto TCP, with the suggested stoichiometry of 2:1 (24), also led to a matrix able to significantly support RGD-independent cell adhesion and spreading (which respectively were 80 ± 1.4 and 98 ± 3.9% of control FN, in a typical experiment with 100 μg/ml RGD peptide). Cells pre-treated with cycloheximide, to rule out secretion of endogenous adhesion molecules, were still capable of RGD-independent cell attachment on tTG-FN (data not shown). Together these data show that binding of tTG to FN supports a novel RGD-independent pathway.

**tTG Immobilization on Amino-terminal FN Fragments Is Not Sufficient to Mediate RGD-independent Adhesion of Osteoblast-like Cells**—Because tTG is known to bind to FN at a domain within the 70 kDa amino-terminal fragment (13, 24) we explored whether association of tTG to N-terminal FN peptides was sufficient to support RGD-independent cell adhesion. tTG was immobilized on the 70 kDa (matrix assembly, heparin and gelatin binding), 45 kDa (gelatin binding) and 30 kDa (first type I repeats, matrix assembly, heparin binding) amino-terminal FN peptides. Detection of the relative levels of tTG by ELISA showed that incubation of the FN fragments with 20 μg/ml tTG resulted in saturating levels of tTG immobilized on all fragments (Fig. 2A). Cell adhesion of HOB cells to the different FN fragments alone or in complex with tTG was compared. On the 70 kDa fragment alone, both cell attachment and spreading in the absence of RGD peptide were ~80% the values obtained on FN (Fig. 2B, upper and lower panels, respectively); however, on the 45 kDa and 30 kDa fragments cell attachment and cell spreading were only ~10 and ~5% of control FN, respectively. In the presence of RGD peptide, cell attachment and spreading values on the 70 kDa fragment were significantly inhibited by ~40% (Fig. 2B, upper and lower panels, respectively). This data agrees with previous findings that the amino-terminal of FN binds the integrin α5β1 in cross-competition with the RGD peptide (12). Immobilization of tTG on the 70 kDa fragment unlike FN did not induce RGD-inde-
Fig. 3. Confocal laser fluorescence microscopy of RGD-independent actin cytoskeleton organization and focal adhesion in response to tTG-FN. A, visualization of actin stress fibers and focal adhesions in the presence of RGD peptide. Cells were seeded as in legend to Fig. 1 and the indicated cells pre-treated with RGD peptide (100 μg/ml) (RGD). Actin stress fibers and focal adhesions were revealed as described under “Experimental Procedures.” Images were acquired by confocal laser fluorescence microscopy, and cells in random fields (at least 100 cells in FN control) were scored for actin stress fiber formation as outlined under “Experimental Procedures.” Ordinate represents the mean percentage of cells with stress fibers expressed as percentage of control values on FN. Mean ± S.D. was 49 ± 8.4 in B, upper panel, and 53 ± 7.8 in B, lower graph. Bars = 10 μm. B, actin stress fibers in the presence of function blocking anti-integrin α5 and β1 antibodies. HOB cells in suspension were pre-incubated with anti-integrin antibodies P1D6 (α5) and JB1A (β1) or control mouse IgGs (IgG) before seeding on either FN or tTG-FN as described in A. At least 200 cells in FN/IgG control were scored. Mean percentage value of cells with actin fibers formed on control FN ± S.D. was 63 ± 5.

negligible regardless of the binding of tTG, and that tTG binding to the 70-kDa peptide is not sufficient to sustain RGD-independent cell adhesion.

RGD-independent Cell Adhesion to FN with Immobilized tTG Promotes Formation of Unique Focal Adhesion Structures—Formation of actin stress fibers in the presence of integrin-binding RGD peptide in response to tTG-FN was analyzed by confocal laser scanning microscopy utilizing FITC-phalloidin. HOB cells adhered to FN did not show organized stress fibers following RGD peptide treatment (Fig. 3A, panel c), compared with non-treated cells (Fig. 3A, panel a), which exhibited a flat morphology and extensive actin stress fibers. In contrast, most of the cells seeded on tTG-FN were spread and had organized actin stress fibers despite the RGD peptide (Fig. 3A, panel a); however, the actin fibers formed were shorter and less organized than those assembled in control cells adhered to FN in the absence of RGD peptide (Fig. 3A, panel a). Without RGD peptide, actin stress fibers appeared more dense and well formed in response to tTG-FN than FN (Fig. 3A, panels b and a, respectively), confirming that immobilized tTG enhances cell spreading (see Fig. 1B). Staining for vinculin indicated the absence of punctate characteristic focal contacts of FN-adhered cells (Fig. 3A, panel c) in the RGD-treated cells adhered to FN (Fig. 3A, panel g) but not in those adhered to tTG-FN (Fig. 3A, panel h). Relative measurement of the formed actin stress fibers (Fig. 3A, graph) confirmed that the RGD peptide did not affect the formation of focal adhesions in cells plated on tTG-FN, although it significantly affected the quality of the actin reorganization, as shown by fluorescence microscopy (Fig. 3A, panel d). Treatment of cells with the function blocking anti-integrin β1 (JB1A) and, to a lesser extent, α5 antibody (P1D6), led to a large decrease of actin stress fibers on FN (Fig. 3B, panels b and c, respectively), compared with cells incubated with nonspecific IgG (Fig. 3B, panel a). In contrast, on tTG-FN, cells incubated with the anti-integrin antibodies appeared to maintain a network of actin stress fibers (Fig. 3B, panels e and f), although less elaborated and dense than in control cells treated with IgGs (Fig. 3B, panel d). Comparison of the number of formed actin stress fibers (Fig. 3B, graph) statistically confirmed these observations that tTG-FN leads to the formation of integrin β1- and α5-independent actin filaments even though more rudimental than in the absence of inhibition. RGD-inde-
Dependent adhesion of cells to tTG-FN was dependent on GTPase RhoA, because inhibition of RhoA activity by botulinum toxin C3 exotransferase almost completely blocked RGD-independent assembly of actin stress fibers in response to tTG-FN (Fig. 3C).

**tTG Cross-linking Activity Is Not Required to Support RGD-independent Cell Adhesion—**We next assayed the transamidating activity of FN-bound tTG to establish its potential role in the described RGD-independent adhesion process. The activity of tTG once bound to FN was negligible when measured in cell culture medium DMEM, which contains an activating concentration of Ca\(^{2+}\) (1.9 mM), and was not changed by addition of further Ca\(^{2+}\), but was significantly boosted by pre-incubation of tTG with DTT prior to immobilization on FN (Fig. 4A), as described previously (26). Hence, under the conditions used FN-bound tTG is not active in the presence of cell culture medium, unless its cysteine residues, particularly the active-site Cys\(^{277}\), are kept in a reduced state. The transamidation-independent role of tTG in the RGD-independent cell adhesion process was confirmed by utilizing the irreversible inhibitor R283, a 2-[(2-oxopropyl)thio]imidazolium derivative (19). HOB cells were incubated with R283 and plated on a tTG-FN matrix pre-treated with R283, in the absence or presence of RGD peptide. Under these conditions the activity of the immobilized tTG is completely blocked by the inhibitor (Fig. 4C). The low tTG activity found at the HOB cell surface (30) is also inhibited to negligible values by equal concentrations of R283.\(^5\) Cell adhesion on FN bound to inactivated tTG was not significantly different from cell adhesion on FN bound to tTG not treated with the inhibitor, with or without pre-treatment of cells with RGD peptide, and it was typically twice cell adhesion on FN in the presence of RGD peptide (Fig. 4B, cell attachment, upper panel; cell spreading, lower panel). These data clearly indicate that FN-bound tTG does not require its transamidation activity to promote RGD-independent cell adhesion.

**Evidence for the Importance of FN-associate tTG and its Calcium-induced Conformation in Cell-surface Recognition—**To assess the importance of tTG in cell-surface interaction, FN-bound tTG was blocked by using the monoclonal anti-tTG antibody Cub74 in conditions that fully preserved the availability of FN in this complex. This was demonstrated by the unchanged recognition of FN by anti-FN polyclonal antibody after treatment of tTG-FN with either Cub74 or control IgG (Fig. 5B). Obstruction of tTG by Cub74 completely abolished the RGD-independent cell adhesion mediated by tTG-FN (Fig. 5A, cell attachment, upper panel; cell spreading, lower panel), suggesting a direct role for FN-associated tTG in the RGD-independent binding to cells. tTG can assume two conformations, depending on whether it is bound to GTP/GDP or Ca\(^{2+}\) (18). In the extracellular environment, tTG is likely to assume the Ca\(^{2+}\)-bound open structure. Incubation of FN-bound tTG with the non-hydrolysable GTP-\(\gamma\)S (1 mM) significantly reduced the RGD-independent cell attachment and spreading mediated by tTG-FN (Fig. 5C, upper and lower panels, respectively). Because incubation of tTG with GTP-\(\gamma\)S did not significantly alter the level of tTG bound to FN (Fig. 5D), our results suggest that RGD-independent cell adhesion to tTG-FN critically depends on the calcium-bridged tertiary structure of tTG.

**Role of Cell-surface Heparan Sulfate in RGD-independent Cell Adhesion and Signaling via tTG-FN—**To explore the possibility that cell adhesion to tTG-FN may be mediated by a cell-surface proteoglycan, HOB cells were treated with glycosaminoglycan-degrading enzymes. Degradation of cell-surface heparan sulfate chains with heparitinase (15 milliunits/ml) led to a reduced cell attachment to FN (−70% of control values) (Fig. 6A, upper panel), as expected given the importance of cell-membrane HSPG in the adhesion of osteoblast-like cells (34). It also led to complete abolishment of RGD-independent cell attachment and spreading on tTG-FN (Fig. 6A, upper and lower panels, respectively). In contrast, equal concentrations of protease-free chondroitinase ABC had no significant effect on cell adhesion to FN, did not significantly alter RGD-independent adhesion.

\(^5\) D. Telci, E. A. M. Verderio, and M. Griffin, unpublished data.

---

**Fig. 4.** tTG cross-linking activity is not required to support RGD-independent cell adhesion to tTG-FN. A, the activity of FN-bound tTG (tTG-FN) was measured by incorporation of biotinylated cadaverine into FN in either culture medium DMEM (DM), or DMEM with 5 mM Ca\(^{2+}\) (DM-Ca\(^{2+}\)), or DMEM supplemented with 5 mM DTT (DM-DTT). Values represent the mean ± S.D. of absorbance at 450 nm of one typical experiment undertaken in triplicate. B, cell adhesion to tTG-FN following inactivation of tTG. The tTG-FN matrix was incubated with the tTG irreversible inhibitor R283 (100 μM) and then utilized as adhesive substrate for HOB cells, further supplemented with the same concentration of R283. In controls, identically treated cells were seeded on tTG-FN without R283 treatment. Where indicated, cells were pre-incubated with RGD peptide (100 μg/ml). Cells were examined for cell attachment (B, upper panel) and cell spreading (B, lower panel) and data expressed as percentage of control values on FN as in the legend to Fig. 1. Mean attachment value on FN control ± S.D., 373 ± 36 in B, upper panel; mean percentage value of spread cells ± S.D. on FN control, 89 ± 6 in B, lower panel; total cells analyzed in control sample, ~1100. Data shown are from a representative experiment undertaken in triplicate. C, inhibition of the cross-linking activity of FN-bound tTG (tTG-FN) and tTG-free in solution (tTG) by 100 μM R283, when measured as described in A, in buffer containing DTT. Values represent the mean ± S.D. of a representative experiment undertaken in triplicate.
RGD-independent Cell Adhesion by Tissue tTG-FN Complex

Fig. 5. RGD-independent cell adhesion to FN-bound tTG depends on tTG accessibility and GTP-mediated conformational change. A, FN-bound tTG was blocked by incubation with Cub74 (40 μg/ml) for 1 h at 37 °C in PBS with 2 mM EDTA using mouse IgG1k as control antibody. Following pre-incubation with RGD peptide, cells were seeded on the tTG-FN matrix. Adhered cells were examined for cell attachment (A, upper panel) and cell spreading (A, lower panel) and data expressed as in the legend to Fig. 1. Mean attachment value ± S.D. on FN control, 229 ± 13 in A, upper panel; mean percentage value of spread cells ± S.D. on FN control, 95 ± 2 in A, lower panel; total cells analyzed in control sample, ∼700. Data are from a typical experiment undertaken in triplicate. B, availability of FN, detected as described under “Experimental Procedures,” after blocking the tTG-FN matrix by Cub74 and IgG1k. Values represent the mean ± S.D. absorbance at 450 nm of 4 replicates from a typical experiment. C, HOB cells in suspension, pre-incubated with RGD peptide (100 μg/ml) as indicated, were seeded in the presence of 1 mM GTP-γS on FN-bound tTG, pre-incubated with 1 mM GTP-γS in PBS for 10 min at room temperature. Adhered cells were examined for cell attachment (C, upper panel) and cell spreading (C, lower panel) with and without inactivation of tTG by GTP-γS and data expressed as in the legend to Fig. 1. Mean attachment value ± S.D. on FN control, 284 ± 98.93 in C, upper panel; mean percentage value of spread cells ± S.D. on FN control, 84.9 ± 4 in C, lower panel; total cells analyzed in control sample, ∼800. Data are from a typical experiment undertaken in triplicate. D, relative levels of tTG that bind FN in the presence of 1 mM GTP-γS, in conditions identical to C above. tTG was detected by an ELISA-type assay described in the “Experimental Procedures.” Values represent the mean ± S.D. absorbance at 450 nm of 4 replicates from a representative experiment.

Fig. 6. RGD-independent cell adhesion to tTG-FN is dependent on cell surface heparan sulfate and PKCα activity. A, HOB cells in suspension (2 × 10^5 cell/ml) were pre-treated with 15 milli-units/ml heparitinase or 15 milliunits/ml protease-free chondroitinase ABC in serum-free medium for 1 h at 37 °C before evaluating cell attachment (upper panel) and cell spreading (lower panel) in the presence of RGD or RAD peptide (100 μg/ml). Data are produced and expressed as in the legend to Fig. 1 and represent percentage of control values on FN from one of 3 separate experiments. Mean attachment values ± S.D. on FN control without peptide treatment (not shown), 140 ± 16; mean percentage values of spread cells on FN control, 89 ± 2; total cells analyzed in control sample, ∼420. B, monolayers of sub-confluent HOB cells were serum-starved for 12 h and then incubated in serum-free DMEM medium supplemented with the PKCα inhibitor Go6976 (5 μM, dissolved in Me2SO) for 1 h or with an equal volume of Me2SO only. Cells were then harvested and analyzed for cell attachment (upper panel) and spreading (lower panel) on FN and tTG-FN. Data, expressed as percentage of control values on FN, are from one of 3 separate experiments. Mean attachment and spread cell values ± S.D. on FN control without peptide (not shown), 197 ± 8 and 83 ± 4, respectively; total cells analyzed in control sample, ∼590.
RGD-independent attachment (over 90%) and spreading (~85%) mediated by the tTG-FN complex (Fig. 6B), indicating that cell adhesion mediated by tTG-FN critically depends on PKCa activity. This finding also hints at syndecan-4 as the likely HSPG responsible for binding the tTG-FN complex.

**RGD-independent Adhesion in Response to tTG-FN Enhances Tyrosine Phosphorylation of FAK**—Having shown that tTG-FN transmits signals via a heparan sulfate receptor leading to cell spreading and that this process depends on the activity of PKCα, we next examined whether the attachment to tTG-FN led to activation of FAK. Tyrosine phosphorylation of FAK in cells plated on FN and treated with RGD peptide was decreased to ~25% of that found in control cells plated on FN and pre-incubated with control RAD peptide (Fig. 7). In response to TG-FN instead, the level of FAK phosphorylation in the presence of RGD peptide was found to be ~60% of the level of both control cells on FN or tTG-FN. This data shows that the RGD-independent cell adhesion mediated by tTG-FN enhances tyrosine phosphorylation of FAK and as such implies FAK as one of the intracellular signaling mediators of tTG-FN.

**RGD-independent Cell Adhesion Can Be Mediated by a Physiological Matrix of Cell-assembled FN and Cell-secreted tTG**—We have previously shown (19, 20, 22, 37) that increased expression of tTG within cells results in an increased export of the enzyme into the extracellular matrix. Such a phenomenon has been observed during cell stress and following cell wounding (16, 17). To produce such a cell model, conditioned matrices of cell-assembled FN with different bound levels of cell-secreted tTG were obtained from a long-term culture of a transfected fibroblast cell line (Swiss 3T3-TG3), capable of tetracycline (tet) amenable to the idea that tTG activity is gradually down-regulated in the presence of reducing agent (Fig. 8). This is consistent with the data of an ELISA-type assay described under “Experimental Procedures.” Values represent the mean ± S.D. of 6 replicates from a representative experiment. C, cross-linking activity of tTG in ECM/TG3+tet and ECM/TG3−tet, measured by the incorporation of biotinylated cadaverine into FN in culture medium DMEM in the absence (DM) or presence of 5 mM DTT (DTT). Data represent the mean ± S.D. of 3 replicates from a typical experiment.

**Levels of RGD peptide, cell attachment was still more effective on the ECM containing cell-secreted tTG (ECM/TG3-tet) than on the ECM containing added tTG (ECM/TG3+tet plus TG). This was despite higher levels of tTG present following exogenous addition of TG (data not shown), suggesting that cell-secreted tTG is better presented to the cell surface. The ECM deposited by cells with increased levels of tTG (ECM/TG3-tet) showed no significant difference in tTG enzymatic activity above background (ECM/TG3−tet) in culture medium, unless in the presence of reducing agent (Fig. 8C). This is consistent with the idea that tTG activity is gradually down-regulated once sequestered in the oxidizing extracellular environment.**

**FN-bound tTG Rescues Primary Dermal Fibroblasts from Anoikis**—A potential physiological function of the tTG-mediated RGD-independent cell adhesion is the protection from apoptosis (anoikis) triggered by inhibition of RGD-dependent adhesion. This phenomenon could occur in tissue injury when changes in the ECM composition lead to reduction of RGD-de-
dependent cell adhesion (5, 8), and the increased externalization and binding of tTG to the FN matrix in response to wounding (16, 17) may result in an alternative adhesion-dependent survival pathway. Non-confluent cultures of mouse dermal fibroblasts devoid of tTG (MDF-TG−/−) were plated on FN or tTG-FN and incubated with RGD peptide under serum-free conditions. After ~15 h, the majority of the RGD-treated cells plated on FN were detached and displayed morphological signs of apoptosis. The extent of endonucleolysis was measured by fluorescent labeling of DNA strand breaks using TUNEL and quantified by flow cytometry (Fig. 9A). After incubation with the RGD peptide ~24% of the total fibroblasts grown on FN were apoptotic (black histogram) compared with only ~2.6% of fibroblasts grown on tTG-FN (blue histogram), which behaved similarly to control cells grown on FN in the absence of RGD peptide (green histogram). These data were corroborated by in situ fluorescent labeling of nuclei undertaken on the detached cells in suspension, which was visualized and scored by confocal microscopy (Fig. 9B). At 15 h exposure to the RGD peptide, a significantly lower number of apoptotic cells were found in the culture fluid of cells grown on tTG-FN compared with FN. The level of apoptosis upon incubation on tTG-FN was comparable with that found in the culture medium of control cells on FN without the RGD peptide (Fig. 9B). After 30 h incubation in the absence of serum, nuclear fragmentation appeared to increase not only in cells grown with RGD peptide but also in cells grown on FN without RGD peptide, thus limiting our investigations to ~15 h time-period (Fig. 9B). We next assayed the viability of MDF-TG−/− in response to tTG-FN (Fig. 9C). Cell viability on FN was significantly decreased after 15-h exposure to RGD peptide, compared with control RAD peptide (Fig. 9C), in agreement with the level of total apoptotic cell death measured in the same conditions by flow cytometry (Fig. 9A). In contrast, cell viability on tTG-FN was not substantially altered by incubation with RGD peptide, and it was found to be ~30% higher than on FN (Fig. 9C), indicating that attachment to tTG-FN mediates RGD-independent cell survival.

**DISCUSSION**

The impact of tTG, a well characterized FN-associating protein and modulator of the FN matrix on FN-mediated cell survival has never been investigated (38). Whereas previous studies have analyzed the roles of tTG by modulating its expression (22, 25, 26, 39), in the present study we have developed a model that allows us to characterize cellular responses to a tTG-rich FN matrix, thus mimicking physio/pathological conditions in vivo. Support for our model comes from findings that tTG is not only externalized under normal physiological conditions but it is also up-regulated, exported, and deposited into the ECM in response to tissue trauma following cellular damage, inflammation, or cell stress (16, 17, 40), where it either binds FN fibrils directly or plasma FN (20, 22, 24), which is then deposited in the damaged area. Hence a complex of tTG and FN, formed as a result of matrix alterations during tissue injury, may provide a mechanism to ensure adhesion-mediated cell survival in wound-repair in response to the reduction or loss of RGD-dependent cell adhesion (8, 5).

To test this hypothesis, we initially examined the function of the tTG-FN complex in cell-matrix interactions whereby we inhibited the “classical” adhesion-mediated survival pathway dependent on the interaction of the FNIII10 RGD cell-binding site with α5β1 integrins. A human osteoblast-like cell line served as the initial cell model because osteoblasts secrete both FN and tTG (30, 34, 41) are subject to continuous matrix remodeling processes during their differentiation, are characterized by a well defined and simple pattern of integrin cell surface receptors, mainly β1, and make use of RGD-independent pathways in the attachment to the ECM (34). We demonstrate that the loss of cell-matrix interaction by inhibition of RGD-dependent integrin function can be largely re-established

![Fig. 9. Cell attachment to tTG-FN promotes cell survival of tTG-null dermal fibroblasts induced to undergo apoptosis by inhibition of RGD-dependent integrin function.](http://www.jbc.org/)

A. Flow cytometric analysis of apoptosis in tTG-null mouse dermal fibroblasts (MDF-TG−/−). Cells were seeded in medium containing RGD peptide (100 μg/ml) or DMEM only, on FN or tTG-FN for 15 h. As a measure of apoptosis, nuclear fragmentation of both adherent and detached cells was detected by TUNEL and quantified by flow cytometry as described under “Experimental Procedures.” The bar denotes the positive region of fragmented nuclei (% apoptotic nuclei), set by the negative standard (n.s.) of cells undergoing anoikis and incubated with FITC-dUTP in the absence of the enzyme TdT (red histogram). Md, median fluorescence channel.

B. In situ analysis of nuclear fragmentation of MDF-TG−/−. Cells were treated with RGD peptide and incubated as described in A. After 15 h and 30 h growth, the fractions of cells in suspension were processed for in situ detection of DNA fragmentation, which was scored by confocal fluorescent microscopy as described under “Experimental Procedures.” Data represent the mean ± S.D. of a typical experiment performed in triplicate.

C. Cell viability on FN or tTG-FN for 15 h, as described above. Cell viability was tested following incubation of cells with XTT. Total cells analyzed, ~450 and ~400 at 15 h and 30 h, respectively. Bar = 10 μm.
upon seeding of cells on either FN with associated tTG or a more physiological matrix of cell-assembled FN containing cell-secreted tTG. This latter form of tTG-FN matrix is thought to be the most important form present in vivo as in tissues, FN is present as an insoluble fibrillar matrix to which tTG is closely associated (20, 22). Restoration of cell adhesion by tTG-FN following RGD inhibition was also found in mouse Swiss 3T3 fibroblasts and in the epithelial-like cells ECV-304, suggesting that many cell types can use the RGD-independent cell-adhesion pathway mediated by tTG-FN.

We demonstrate that cell adhesion to tTG-FN is not linked to modification of FN by calcium-dependent transamidation. This finding is consistent with recent observations indicating a transamidating-independent role for tTG in cell-matrix interactions (19, 27, 28). Moreover we show that when tTG is complexed with FN it becomes catalytically inactive unless kept in a reduced state. Indeed, previous work has described that tTG sequestration by FN leads to down-regulation of enzymatic activity on large-size protein substrates (24). In contrast, in situ tTG activity demonstrated with small-size fluorescent primary amine substrate has clearly shown that tTG is catalytically active while present at the cell surface (22). tTG may modify FN by its intrinsic protein disulfide isomerase (PDI) activity, which has been recently ascribed to it (42). However, because GTP binding to tTG affects the adhesion function of FN-bound tTG but does not affect the PDI activity of tTG this possibility seems unlikely.

The outside-in signaling induced by the RGD-independent cell adhesion to tTG-FN appears to result by direct interaction of tTG with the cell surface, because the blocking of tTG accessibility by a monoclonal antibody greatly reduces this process. The calcium-mediated tertiary structure of tTG is also required, suggesting that crucial cell-binding sites might be exposed when tTG assumes the calcium-induced open conformation. However, the simple binding of 20 µg/ml tTG to either tissue culture plastic or the gelatin-binding domain of FN, which contains the tTG-binding site (13), does not enhance cell adhesion, which is indeed equally negligible regardless of the presence of tTG, in contrast to what has been previously reported (27, 28). We also found that tTG binding to the 70 kDa amino-terminal fragment of FN, which can support cell adhesion and includes the tTG-binding site, is not sufficient to sustain tTG-mediated RGD-independent cell adhesion. This leads us to conclude that the RGD-independent adhesion to tTG-FN is both tTG- and FN-dependent, with the amino-terminal of FN required to support tTG binding and the carboxy-terminal of FN and/or cryptic epitopes outside the FNIII9-10 domains, essential to sustain the RGD-independent pathway.

Our data also suggest that the RGD-independent cell adhesion to tTG-FN is integrin-independent or, alternatively, the integrin must be in partnership with some other receptor(s). This observation is supported by the finding that tTG-mediated focal adhesions still formed in the presence of function blocking anti-integrin antibodies β1 and α5, which cause conformational inactivation of the receptor, thus preventing outside in signaling (43). Under these conditions the actin stress fibers formed appeared less complex than normal, nevertheless the cytoarchitecture was sufficient for the formation of distinct RGD-independent focal adhesions, which are mediated by GTPase RhoA and induce FAK tyrosine phosphorylation. Therefore, modulation of matrix FN by tTG adds to the increasing number of non-integrin-mediated stimuli, which enhance FAK activity through actin polymerization (44). The possibility that tTG-FN may mediate RGD-independent cell adhesion through the αβ1-induced RGD-independent pathway is also unlikely because low or negligible levels of α4 subunit are generally expressed in osteoblasts (34). Moreover, matrix binding to α5β1 does not generate actin stress fibers (45). Although tTG association with integrins is documented, our data suggest that it is more likely that the cell function induced by tTG-FN results from the binding to non-integrin receptors. Given the high affinity binding of tTG for heparin (46), a possible candidate receptor for tTG-FN is that belonging to the class of HSPG (35). Treatment of HOB cells with heparitinase but not chondroitinase ABC greatly diminished the RGD-independent adhesion in response to tTG-FN, suggesting that cell surface HSPG may mediate RGD-independent cell adhesion to tTG-FN. The C-terminal HepII domain of FN is responsible for the synergistic interaction of FN with cell surface heparan sulfate and integrins, and this interaction is essential for optimal cell adhesion and critical for sustained cell survival (7, 35). Association of tTG with FN could induce RGD-independent cell adhesion by reinforcing HSPG-mediated adhesion, through a dual mechanism involving the binding of tTG to cell surface HSPG and increased exposure of the C-terminal heparin-binding domain of FN, which critically depends on FN structure (9). The increased cell spreading observed in osteoblasts and Swiss 3T3 fibroblasts in early cell adhesion to tTG-FN also in the absence of integrin inhibition suggests that HSPG receptors are not fully occupied when cells are normally seeded on a FN matrix and that increased binding occurs in response to tTG-FN. Downstream signaling from syndecan-4, the only HSPG that is a widespread component of focal adhesion, specifically results in hyperactivation of PKCα and activation of both RhoA and FAK (7, 35). Our results suggest that RGD-independent cell adhesion mediated by tTG-FN requires PKCα activity because the compound Go6976, which is the only inhibitor available that shows specificity for PKCα (36), blocks this process. Our data also show that the function of FN-bound tTG depends on RhoA activation and is linked to activation of the cell survival kinase FAK (1, 44).

Moreover, in preliminary investigations using a Raf-1-null 3T3 like immortalized fibroblast cell line (47) we could demonstrate that the RGD-independent cell adhesion pathway by tTG-FN is not functional in this cell line. This suggests that the Raf protein, whose main function is anti-apoptotic (47), may be a key component in the signaling pathway mediated by tTG-FN. The observation that a tTG-FN matrix can rescue tTG-null primary dermal fibroblasts from anoikis with maintenance of cell viability is therefore consistent with its activation of intracellular survival mediators. Importantly, it shows that the survival role of tTG is essentially extracellular and not intracellular as recently suggested by Antonyak et al. (48), following up-regulation of tTG by retinoic acid.

It is now accepted that RGD-mediated cell adhesion is not sufficient in isolation to maintain cell survival. For sustained survival cells need to interact with “complex” ECMs via integrin and non-integrin receptors, such as cell surface proteoglycans (7). Interestingly like tTG, increased expression of syndecan-4 is also found at sites of tissue injury (35). The work presented here indicates that binding of tTG to FN represents one additional survival signal by inducing heparan-sulfate receptors-mediated cell adhesion, which can either act in synergy or in alternative to integrin RGD-dependent cell adhesion at sites of tissue injury.

Acknowledgments—We thank Dr. M. Baccarini (Vienna Biocenter, Vienna, Austria) for critically reading the manuscript and for donating the Raf-1-null 3T3-like immortalized fibroblasts and M. Stevenson for help with the compilation of the manuscript.

3 D. Telci, E. A. M. Verderio, M. Baccarini, and M. Griffin, unpublished data.
RGD-independent Cell Adhesion by Tissue tTG-FN Complex

REFERENCES
1. Frisch, S. M., and Screaton, R. A. (2001) Curr. Opin. Cell Biol. 13, 555–562
2. Boudreaux, N., Sympon, C. J., Werb, Z., and Risdell, M. J. (1995) Science. 267, 891–893
3. Davis, G. E., Bayless, K. J., Davis, M. J., and Meininga, G. A. (2000) Am. J. Pathol. 156, 1489–1498
4. Sechler, J. L., and Schwarzhauser, J. E. (1998) J. Biol. Chem. 273, 25533–25536
5. Hadden, H. L., and Henke, C. A. (2000) Am. J. Respir. Crit. Care Med. 162, 1553–1560
6. Buckley, C. D., Pilling, D., Henriques, N. V., Parsonage, G., Threlfall, K., Scheel-Toellner, D., Simmons, D. L., Akbar, A. N., Lord, J. M., and Salmon, M. (1999) Nature 397, 584–589
7. Jeong, J., Lim, Y., Kim, J., Parks, I., Wood, A., Couchman, J. R., and Oh, E. S. (2001) Biochem. J. 356, 231–237
8. Kapila, Y. L., Wang, S., and Johnson, F. W. (1999) J. Biol. Chem. 274, 30996–309913
9. Sharma, A., Askari, J. A., Humphries, M. J., Jones, E. Y., and Stuart, D. I. (1995) EMBO J. 14, 1468–1479
10. Aeschlimann, D., and Thomas, V. (2000) Connect Tissue Res. 41, 1–27
11. Pereira, M, Rybarczyk, B. J., Odrljin, T. M., Hocking, D. C., Sottile, J., and Haroon, Z. A., Hettasch, J. M., Lai, T. S., Dewhirst, M. W., and Greenberg, M. (1999) J. Biol. Chem. 274, 5654–5658
12. Verderio, E., Nicholas, B., Gross, S., and Griffin, M. (1998) J. Biol. Chem. 273, 10673–10682
13. Radek, J. T., Jeong, J. M., Murthy, S. N., Ingham, K. C., and Lorand, L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3152–3156
14. Griffin, M., Casaduo, R., and Bergamini, C. M. (2002) Biochem. J. Rev. 368, 377–396
15. Fesus, L., and Piacentini, M. (2002) Trends Biochem. Sci. 27, 534–539
16. Haroon, Z. A., Hettasch, J. M., Lai, T. S., Dewhirst, M. W., and Greenberg, C. S. (1999) PASEB J. 13, 1787–1795
17. Johnson, T. S., Skill, N. J., El Nahas, A. M., Oldroyd, S. D., Thomas, G. L., Deutswaite, J. A., Hayls, J. L., and Griffin, M. (1999) J. Am. Soc. Nephrol. 10, 2146–2157
18. Liu, S., Cerione, R. A., and Clardy, J. (2000) Proc. Natl. Acad. Sci. U. S. A. 99, 2743–2747
19. Balklava, Z., Verderio, E., Colligan, R., Gross, S., Adams, J., and Griffin, M. (2002) J. Biol. Chem. 277, 16567–16575
20. Gaudry, C. A., Verderio, E., Aschlimann, D., Cox, A., Smith, C., and Griffin, M. (1999) J. Biol. Chem. 274, 36707–36714
21. Jeong, J. M., Murthy, S. N., Radek, J. T., and Lorand, L. (1995) J. Biol. Chem. 270, 5654–5658
22. Verderio, E., Nicholas, B., Gross, S., and Griffin, M. (1998) Exp. Cell Res. 239, 119–138
23. Belkin, A. M., Akimov, S. S., Zartitskaya, L. S., Ratnikov, B. I., Deryugina, E. I., and Strongin, A. Y. (2001) J. Biol. Chem. 276, 18415–18422
24. LeMesy, E. K., Erickson, H. P., Beyer, W. F., Radek, J. T., Jeong, J. M., Murthy, S. N., and Lorand, L. (1999) J. Biol. Chem. 267, 7880–7885
25. Gentile, V., Thomany, V., Piacentini, M., Fesus, L., and Davies, P. J. (1992) J. Biol. Chem. 118, 463–474
26. Jones, R. A., Nicholas, B., Mian, S., Davies, P. J., and Griffin, M. (1997) J. Cell Sci. 110, 2461–2472
27. Akimov, S. S., Krylov, D., Fleischman, L. F., and Belkin, A. M. (2000) J. Cell Biol. 148, 925–938
28. Takahashi, H., Isohe, T., Horibe, S., Takagi, J., Yokosaki, Y., Sheppard, D., and Saito, Y. (2000) J. Biol. Chem. 275, 23589–23595
29. Leblanc, A., Day, N., Menard, A., and Keillor, J. W. (1999) Protein Expr. Purif. 17, 89–95
30. Verderio, E., Coombes, A., Jones, R. A., Li, X., Heath, D., Downes, S., and Griffin, M. (2000) J. Biomed. Mater. Res. 54, 284–304
31. De Laurenti, V., and Melino, G. (2001) Mol. Cell. Biol. 21, 148–155
32. Dedbrar, S., Ruslahti, E., and Pierschbacher, M. D. (1997) J. Cell Biol. 104, 585–593
33. Heath, D. J., Christian, P., and Griffin, M. (2002) Biomaterials. 23, 1519–1526
34. Grotios, S., Stewart, K., Graves, S. E., Hay, S., and Simmons, P. J. (1997) J. Bone Miner. Res. 12, 1189–1197
35. Woods, A., and Couchman, J. R. (2001) Curr. Opin. Cell Biol. 13, 578–583
36. Geschwendt, M., Dietersch, S., Rennecke, J., Kistkein, W., Muller, H. J., and Johannes, F. J. (1996) FEBS Lett. 392, 77–80
37. Verderio, E., Gaudry, C. A., Gross, S., Smith, C., Downes, S., and Griffin, M. (1999) J. Histochem. Cytochem. 47, 1417–1432
38. Lorand, L., and Graham, R. M. (2003) Nat. Rev. Mol. Cell. Biol. 4, 140–156
39. Melino, G., Thiele, C. J., Knight, R. A., and Piacentini, M. (1997) J. Neurooncol. 31, 65–82
40. Upchurch, H. F., Conway, E., Patterson, M. K., Jr., and Maxwell, M. D. (1991) J. Cell. Physiol. 149, 375–382
41. Heath, D. J., Downes, S., Verderio, E., and Griffin, M. (2001) J. Bone Miner. Res. 16, 1477–1485
42. Hasegawa, G., and Saito, Y. (2002) Minerova Biotecnologica. 14, 192
43. Humphries, M. J. (2000) Trends Pharmacol. Sci. 21, 29–32
44. Schlaepfer, D. D., Hauck, C. R., and Sieg, D. J. (1999) Prog. Biophys. Mol. Biol. 71, 435–478
45. Sechler, J. L., Cumiskey, A. M., Gazzola, D. M., and Schwarzhauser, J. E. (2000) J. Cell Sci. 113, 1491–1496
46. Bergamini, C. M., and Signorini, M. (1993) Biochem. J. 291, 37–39
47. Mikula, M., Schreiber, M., Husak, Z., Kucerova, L., Ruth, J., Wieser, R., Zatloukal, K., Beug, H., Wagner, E. F., and Baccarini, M. (2001) EMBO J. 20, 1592–1602
48. Antonyak, M. A., Singh, U. S., Lee, D. A., Boehm, J. E., Combs, C., Zgola, M. M., Page, R. L., and Cerione, R. A. (2001) J. Biol. Chem. 276, 35582–35587
A Novel RGD-independent Cell Adhesion Pathway Mediated by Fibronectin-bound Tissue Transglutaminase Rescues Cells from Anoikis
Elisabetta A. M. Verderio, Dilek Telci, Afam Okoye, Gerry Melino and Martin Griffin

J. Biol. Chem. 2003, 278:42604-42614.
doi: 10.1074/jbc.M303303200 originally published online May 5, 2003

Access the most updated version of this article at doi: 10.1074/jbc.M303303200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2003/09/03/M303303200.DC2

This article cites 48 references, 23 of which can be accessed free at
http://www.jbc.org/content/278/43/42604.full.html#ref-list-1